Dr. Biran on Patient-Reported Outcomes Following Transplant in Multiple Myeloma

Video

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses patient-reported outcomes following autologous stem cell transplantation in multiple myeloma.

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses patient-reported outcomes following autologous stem cell transplantation (ASCT) in multiple myeloma.

The study looked at patient-reported outcomes, financial toxicity, and cognitive function in patients who undergo autologous stem cell transplant. It is a pilot study with the purpose of obtaining information on feasibility, so that researchers can receive more grant to study a larger group of patients, says Biran.

Twenty-two patients completed pre- and post-ASCT assessments. Median age was 66. From pre- to 6-months post-ASCT, patients reported a reduction in anxiety, depression, fatigue, and pain interference. The study also reported a higher incidence of satisfaction with participation in social roles and physical function.

Biran states that approximately 75 patients have enrolled on the study to date. A preliminary analysis showed that there was also an improvement in financial stress, neuropathy, mobility, and overall cognitive function. This was based on common terminology criteria for adverse events for patients who have undergone the operation.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute